ICER jeopardizes access to new sickle cell treatments

ICER jeopardizes access to new sickle cell treatments

Patients living with sickle cell disease could run into more insurance barriers as a result of a pending report on two potentially groundbreaking SCD treatments. The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun...